Amuvatinib hydrochloride primarily acts by blocking the ATP-binding site of the kinase domain of the RET protein, thereby inhibiting its autophosphorylation. It targets c-Kit (D816H), c-Kit (D816V), c-Kit (V560G), c-Kit (V654A), PDGFRα (D842V), and PDGFRα (V561D).
Amuvatinib hydrochloride serves as a c-Ret inhibitor used in researching targeted cancer therapies, particularly for tumors with c-Ret mutations.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.